Telemedicine for Patients With an Hybrid Closed Loop System

A Telemedicine Platform for Patients With Type 1 Diabetes Mellitus Treated With an Hybrid Closed Loop System

The primary objective is to assess the impact on quality of life after a follow-up program using a telemedicine platform designed for patients with DM1 treated with an hybrid closed loop insulin infusion system. Open-label, randomized 1:1 controlled clinical trial during 12 months.

Inclusion Criteria:

• Diagnostic criteria for DM1 according to ADA
• They must have access to the technology that allows monitoring (mobile phone and / or computer as well as having an internet connection)
• Acceptance of participation in the study and signing of the informed consent

Exclusion Criteria:

• Gestation
• Institutionalization, serious or terminal illness or renal replacement therapy.
• Inability to undertake the training and / or acquire the degree of knowledge to use the telemedicine platform.
• Refusal to participate in the study or to sign the informed consent